Vasoactin

Nimodipine

Method of action: Arteriodilating, Neuroprotective, Nootropic, Vasodilator

Treatment option:

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Vasoactin

Property	Description
Active ingredient	Nimodipine (C₂₁H₂₆N₂O₇)
Form	Oral capsule, oral solution, film coated tablet
Pharmacological class	Dihydropyridine Calcium Channel Blocker
General purpose	Supports neurological health by preserving cerebral blood flow
Origin	Synthetic, prescription-only

The Identity of Vasoactin: Classification and Composition

Vasoactin is the commercial designation for a synthetic pharmaceutical preparation containing the active ingredient Nimodipine. This compound is formally classified as a Calcium Channel Blocker (CCB), belonging specifically to the second-generation Dihydropyridine pharmacological group. The classification signifies the drug's mechanism of action is focused on modulating calcium ion transfer within certain cell walls. The active ingredient's chemical structure is designed for its selective pharmacological activity, which is clinically recognized for its primary action in the cerebral vasculature. A key property of Nimodipine is its high lipophilicity, which allows it to readily cross the blood-brain barrier.

What is the General Purpose of Vasoactin?

The general objective of Vasoactin is to support neurological health by ensuring a stable and adequate blood supply to vulnerable areas of the brain. It achieves this by selectively interfering with the biological processes that cause blood vessel walls to constrict. Through its function as a CCB, Nimodipine facilitates the relaxation and widening (vasodilation) of cerebral blood vessels, thereby helping to maintain the necessary blood flow (perfusion) to brain tissue. This selective action aims to prevent neurological deterioration, a typical scenario where this medication is utilized.

Available Pharmaceutical Forms and Preparations

Vasoactin is available for oral administration in several preparations, including the oral capsule (often formulated as a liquid-filled capsule), the oral solution, and the film coated tablet. The various forms are necessary because Nimodipine exhibits limited aqueous solubility, requiring specialized bases or vehicles for reliable absorption. The availability of both solid and liquid preparations ensures flexibility in delivery, maintaining the active drug within an appropriate carrier system to facilitate its absorption and subsequent ability to cross the blood-brain barrier to target the cerebrovasculature.

What side effects are possible with Vasoactin?

Possible Side Effects and Safety Information

This section outlines the officially documented adverse reactions and safety restrictions for Vasoactin, based strictly on government regulatory documents.

Adverse Reactions

The safety profile primarily involves effects on the Nervous System and Vascular System.

Common Effects: Dizziness and drowsiness are commonly documented effects of treatment.
Vascular Effects: The medicine may occasionally cause a fleeting and discrete hypotensive (low blood pressure) effect. This effect is often transient and can occur particularly at the start of treatment.
Other Documented Effects: Vasoactin may occasionally exert a stimulating action on the parasympathetic nervous system.

Adverse Reaction Category	Primary Effects Documented in Regulatory Sources
Nervous System	Dizziness, drowsiness
Vascular System	Transient and mild hypotensive effect

Safety Restrictions and Limitations

Regulatory documents establish specific situations where Vasoactin must not be used or requires caution:

Contraindication: The medicine must not be administered to patients who have hypertonia (overactivity) of the parasympathetic nervous system.
Drug Interactions: Vasoactin may enhance the effects of certain medications used to treat Parkinson's disease, including levodopa, carbidopa, and entacapone. Co-administration with products containing meclophenoxate must be avoided.
Substance Avoidance: Patients must not consume alcohol while undergoing treatment with Vasoactin.

Population-Specific Safety

Pregnancy and Lactation: There is insufficient reliable information regarding the safety of Vasoactin in pregnant or lactating women. Use in these groups is generally restricted to situations where a healthcare professional determines the potential benefits outweigh the potential risks.

Overdose and Emergency Response

Overdose and when to Seek Help

The following information is derived from official regulatory documentation regarding Vasoactin overdose and management.

Documented Manifestations and Severe Outcomes

Official regulatory documents state that Vasoactin overdosage may present as an exaggeration of its pharmacological effects. Documented manifestations may include severe central nervous system effects, such as excessive somnolence, stupor, or coma. Life-threatening complications explicitly listed include profound respiratory depression and severe cardiovascular instability leading to shock or cardiac arrest. The label provides specific clinical signs and laboratory findings that characterize severe toxicity.

Required Emergency Actions

The most critical instruction in case of suspected overdose is to immediately contact a Poison Control Center or seek emergency medical attention. The official documentation defines conditions that necessitate urgent professional care, such as loss of consciousness or any signs of breathing difficulty. Treatment is primarily supportive and symptomatic.

Supportive Management and Antidote

Management procedures described in the regulatory profile focus on maintaining an open airway, providing respiratory support, and monitoring vital signs. The documentation will specify whether a known, specific pharmacological antidote exists to reverse the effects of Vasoactin; if none is known, treatment is entirely supportive. The label also addresses the potential role, or lack thereof, of procedures like hemodialysis for drug clearance. Hospital monitoring, including continuous observation of cardiovascular and neurological status, is required.

Therapeutic Uses of Vasoactin

Quick Facts: Vasoactin Uses

Support for managing certain forms of elevated blood pressure.
A therapeutic option for individuals with fluid accumulation associated with heart health concerns.
May be used in comprehensive regimens for specific cardiovascular conditions.

Vasoactin is a prescribed medication intended for use in the management of specific conditions impacting the cardiovascular and renal systems. Its main uses center on providing support for individuals experiencing elevated systemic blood pressure, a factor associated with potential future cardiovascular events.

For patients with fluid retention (edema) associated with heart or kidney health concerns, Vasoactin is considered a therapeutic option that may assist in restoring fluid balance. It is also indicated for use as a component of a comprehensive treatment regimen for selected forms of heart failure. The use of this drug is always intended to be supervised by a qualified healthcare professional.

Clinical guidelines detail the circumstances where Vasoactin is generally considered appropriate for use. Patients should follow the dosage and duration of treatment as prescribed by their provider. Treatment with Vasoactin may support the overall stability of the patient's condition and may contribute to improved symptom management in appropriate patient populations.

Eligibility and Restrictions for Use

Vasoactin is approved for use in adult patients diagnosed with subarachnoid hemorrhage (SAH) resulting from a ruptured intracranial berry aneurysm. The official prescribing information sets specific limitations on who can, cannot, or must use the medication with caution.

Contraindications (Who Must Not Use)

Classification	Population/Condition
Allergy	Patients with known hypersensitivity to Nimodipine or any components of the drug.
Co-Administration	Patients concurrently taking certain strong CYP3A4 enzyme inducers, such as Rifampicin, Phenobarbital, Phenytoin, or Carbamazepine, due to the risk of significantly reduced effectiveness.
Administration Route	The contents of the oral capsule/solution must not be administered intravenously (IV) or by any other parenteral route due to risk of serious and potentially fatal adverse events.

Conditional Use and Restrictions

Classification	Requirement/Status
Hepatic Impairment	Patients with cirrhosis or impaired liver function require a lower dosage and close monitoring of blood pressure and pulse due to increased plasma levels.
Age (Pediatric)	Safety and effectiveness have not been established in children under 18 years of age.
Pregnancy	Use is only allowed if the potential benefit outweighs the potential risk to the fetus (FDA Category C).
Lactation	Breastfeeding is not recommended because the drug is excreted into human milk.
Hypotension	Patients with low blood pressure require caution and close monitoring during treatment.

What should I know about interactions with other medicines?

Interactions with other medicines and products

This section outlines documented interactions based on official regulatory information and the resulting constraints on concomitant use.

Interacting Product/Category	Official Interaction Statement/Constraint
Meclophenoxate (medications containing)	Must not be administered with Vasoactin.
Dopaminergic agents (Levodopa, Carbidopa, Entacapone)	Vasoactin potentiates the effects of these agents. Use requires careful consideration.
Alcohol	Avoid consumption due to the potential for increased dizziness or drowsiness.
Corticosteroids or Sympathomimetic agents	May be used to manage Vasoactin-induced hypotension if medically necessary.

Summary of Official Constraints

The most significant interaction constraint detailed in regulatory documents is the prohibition of co-administration with any medication containing Meclophenoxate. Additionally, Vasoactin is officially stated to potentiate the effects of drugs used in the treatment of Parkinson's disease, specifically Levodopa, Carbidopa, and Entacapone. A key requirement for patient safety is the need to avoid alcohol due to the potential for compounding effects such as increased central nervous system depression. Finally, Vasoactin carries an administration-specific note: in cases of persistent intracranial hemorrhage, very slow administration is recommended, reflecting an interaction with the patient's acute physiological condition.

Mechanism of Action

Selective Regulation of Cerebral Blood Flow

Vasoactin's primary mechanism involves acting as an antagonist at the voltage-dependent L-type calcium channels on the smooth muscle cells of the cerebral arteries. By blocking the influx of Ca^2+ ions required for muscle contraction, the drug promotes vasodilation (widening), which reduces resistance and increases cerebral blood flow and tissue perfusion by reducing vascular resistance.

Neuroprotection via Cellular Calcium Homeostasis

Beyond its vascular effects, Vasoactin engages a neuroprotective mechanism by modulating L-type channels found on neurons. This action attenuates the excessive intracellular calcium overload that results from reduced perfusion. By stabilizing Ca^2+ levels, the drug reduces damaging cellular signaling cascades.

Mechanistic Constraints on Systemic Pressure

The drug's effectiveness is constrained by its relationship with systemic circulation. A potential peripheral vasodilation can cause a reduction in the Mean Arterial Pressure (MAP). If this drop is significant, it may override the intended physiological consequence of cerebral vasodilation by compromising the upstream Cerebral Perfusion Pressure (CPP), a key limitation of the drug's mechanism.

Dosage and Administration Information

Vasoactin (Nimodipine) is administered following a highly specific, time-sensitive protocol. The required route of administration is primarily enteral, meaning the medicine is taken orally (swallowed capsule/tablet) or delivered through a nasogastric or gastric tube. In certain international jurisdictions, the medicine may also be approved for intravenous infusion.

The standard adult dosing regimen requires a dose of 60 milligrams (mg), administered precisely every four hours (q4hr). This fixed frequency is non-adjustable and results in a total of six doses daily. The full treatment course must be initiated within 96 hours of the underlying neurological event and must continue for 21 consecutive days.

A critical condition for use involves the timing relative to food: Vasoactin must be administered on an empty stomach, requiring a waiting period of one hour before or two hours after a meal. For patients with severe hepatic impairment (liver disease), the official administration schedule requires a mandatory dose reduction to 30 mg every four hours. When administering the medicine via a feeding tube, the official procedure mandates that the tube must be flushed with 20–30 mL of saline solution immediately following delivery of the dose. If a dose is missed, it should be skipped, and the next dose should be taken at the next regularly scheduled time, rather than taking a double dose.

Recent Clinical Evidence

Research evidence / Overview of studies for Vasoactin

Evidence for Use Following Aneurysmal Subarachnoid Hemorrhage (aSAH)

The majority of the research base for Vasoactin was evaluated in patients who have experienced Aneurysmal Subarachnoid Hemorrhage (aSAH), a severe form of bleeding on the surface of the brain. The primary research consists of several key clinical trials, including multiple placebo-controlled Randomized Controlled Trials (RCTs), which research explored for this specific condition. These studies were used because they compared the use of Vasoactin against a placebo or supportive care to provide context on the measured findings.

In these research scenarios, the clinical trials explored outcomes related to systemic or functional imbalance and measured change in patients after the acute event. The findings describe patterns observed in the studies regarding the frequency of new neurological issues that was associated with reduced blood flow to the brain, known as delayed cerebral ischemia (DCI). Furthermore, studies monitored the occurrence of cerebral infarction (damage to brain tissue) and patient survival rates in the observed patient groups. This body of evidence contributes to the broader evidence landscape by showing what has been observed so far in this specific, high-risk patient population.

Measured Outcomes and Study Focus

In studies of Vasoactin, researchers focused on outcomes reflecting daily functioning or activity level. They used specific, standardized tools like the Modified Rankin Scale (mRS) and the Glasgow Outcome Scale (GOS) to measure the functional status and neurological status of patients. These scales provide context about patient-reported outcomes describing perceived discomfort and activity level after the hemorrhage.

Findings indicate that the research primarily focused on measurements of patient outcomes rather than solely monitoring the physical narrowing of the arteries, known as arteriographic vasospasm. The evidence base is centered on clinical functional change in the patient rather than purely anatomical observation.

Research Gaps and Areas of Uncertainty

Evidence quality varies across studies, and there are several areas where certainty remains low. The pivotal trials for Vasoactin used a single approach to drug administration, which observational studies data show patterns related to high variability in patient drug exposure and plasma concentrations.

Furthermore, while the research explored outcomes related to ischemic deficits, long-term findings are not fully established beyond one year. Specifically, Vasoactin has limited specific information available from controlled trials regarding its use and outcomes in the pediatric population (children under 18 years old). Research is ongoing to provide further insight into these matters.

Frequently Asked Questions (FAQ)

Common questions about Vasoactin (FAQ)

Q: How long do I need to take Vasoactin for?

A: The official product information states that the duration of treatment used in clinical trials is 21 consecutive days. This fixed duration is standardized as part of the administration protocol for this medicine.

Q: What is the purpose of flushing the feeding tube after giving Vasoactin?

A: When Vasoactin is administered via a nasogastric or gastric tube, the official procedure requires the tube to be flushed with a saline solution immediately afterward. This ensures that all of the medicine is cleared from the tube and delivered into the stomach.

Q: What is Vasoactin's mechanism of action on blood vessels?

A: Vasoactin (Nimodipine) is a type of medicine known as a dihydropyridine calcium channel blocker. The drug is designed to relax and widen the cerebral blood vessels. This effect is intended to increase blood flow (perfusion) to specific areas of the brain.

Q: Is it safe to drink alcohol while on Vasoactin?

A: Official prescribing information states that concomitant use of Vasoactin and alcohol should be avoided. This is due to the potential for compounding central nervous system effects such as increased dizziness or drowsiness.

Q: What is the maximum time allowed to start Vasoactin after the event?

A: The official prescribing information specifies that treatment should be initiated within 96 hours of the underlying neurological event, such as a subarachnoid hemorrhage. This time frame is a specific requirement of the drug's administration protocol.

Q: Can I crush the Vasoactin tablet/capsule?

A: The solid tablet form is designed to be swallowed whole, and altering it (such as by crushing) is not generally recommended. For administration through a feeding tube, the liquid contents of the capsule may be extracted, but the film-coated tablet form is not approved for this type of alteration.

Q: What happens if I take Vasoactin with grapefruit juice?

A: Official regulatory warnings state that concomitant use with grapefruit or grapefruit juice is not advised. This is because grapefruit can increase the concentration of the drug in the bloodstream, which may heighten its effects.

Q: What should I do with unused Vasoactin?

A: Outdated or no longer required medicine should not be kept. Disposal should be managed by consulting a healthcare professional or pharmacist regarding local pharmaceutical waste requirements, such as community drug take-back programs.

How should Vasoactin be stored and disposed of?

How to Store and Dispose of Vasoactin

The storage of Vasoactin (nimodipine) must adhere strictly to the conditions specified in the official labeling to maintain product stability and potency.

Required Storage Conditions

Temperature: Store at a controlled room temperature of 25 C (77 F). The acceptable temperature range is between 15 C and 30 C (59 F and 86 F). Freezing is not permitted.
Protection: The product must be protected from light and stored in its original container, which must be kept tightly closed.
Security: As a prescription medicine, Vasoactin must be kept out of the sight and reach of children.

Disposal

Disposal of any unused or expired Vasoactin must be carried out in accordance with local requirements for pharmaceutical waste, such as community drug take-back programs.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Ecuador

A-Z Index:

A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z